LORRAIN DANIEL S. (Chief Scientific Officer) sold 2.6% of their position (4.17K shares) of CONTINEUM THERAPEUTICS, INC. on the open market
Open‑market sale worth $62.3K — a minor trim. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 2 sales
Filed: 2/5/2026ACC: 0001437749-26-003212
Officer· Chief Scientific Officer
Since Mar 2026
-4.17K
Net shares
Net seller
$62.3K
Total sold
2
Open market trades
0B · 2S
2
Total transactions
4.17K disposed
Non-Derivative Transactions2
Class A Common Stock
Direct
Shares
−3K
Price / share
$14.82
Trade value
$44.47K
% of position
1.9%
2/3/2026
160.22K→157.22K
Class A Common Stock
Direct
Shares
−1.17K
Price / share
$15.25
Trade value
$17.84K
% of position
0.7%
2/3/2026
157.22K→156.05K
Total
Net shares
−4.17K
Net value
-$62.31K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Class A Common Stock Direct | 2/3/2026 | S · Sale | −3K | $14.82 | $44.47K | 1.9% | 160.22K | 157.22K |
| Class A Common Stock Direct | 2/3/2026 | S · Sale | −1.17K | $15.25 | $17.84K | 0.7% | 157.22K | 156.05K |
| Total | −4.17K | -$62.31K | ||||||
Derivative Transactions0
No derivative transactions reported
Non-Derivative Holdings (Post-Transaction)1
Class A Common Stock
IndirectShares owned6.84K
Total
6.84K indirect6.84K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Class A Common Stock | 6.84K | Indirect |
| Total | 6.84K | 6.84K indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported